Robert Busch, MD: Topline Results of EMPEROR-REDUCED

from Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives · host Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

In this episode we will be discussing reaction to topline results from the EMPEROR-REDUCED trial examining the use of empagliflozin for heart failure in patients with and without diabetes with endocrinologist Dr. Robert Busch.Announced on July 30, by Berringer Ingelheim and Lilly,topline results indicate use of empagliflozin was associated with a decrease in the composite endpoint of CV death and worsening heart failure. Scheduled to be presented at ESC 2020, the results will be presented 1 year after the results of DAPA-HF.Now, results of EMPEROR-REDUCED have a chance to firmly cement the notion that the benefit on heart failure proven in clinical trials with dapagliflzoin and potentially empaglfilziin is truly a class effect of SGLT2s.

Episode metadata supplied by the publisher feed · Published Jul 31, 2020

Embed this episode

Attribution link and audio player

NOW PLAYING

Robert Busch, MD: Topline Results of EMPEROR-REDUCED

0:00 17:14

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives?

This episode is 17 minutes long.

When was this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode published?

This episode was published on July 31, 2020.

Can I download this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!